Analysts’ Viewpoint on Cancer Biomarkers Market Scenario
Cancer biomarkers play an important role in the early diagnosis of cancer and personalization of cancer treatments. Increase in prevalence of various types of cancers, rise in geriatric population across the world, and growth in technological advancements in development of cancer biomarkers are some of the key factors expected to drive the global cancer biomarkers market during the forecast period. Increase in usage of CEA biomarkers and HER2 biomarkers for detection of cancers such as breast cancer, ovary cancer, thyroid cancer, and small cell lung cancer is also projected to drive the market in the next few years. Leading players are focusing on research and development activities in biomarkers to gain lucrative revenue opportunities in the global cancer biomarkers market.
Biomarker, or biological marker, is a measurable indicator of some biological state or condition. Cancer biomarkers are biomolecules that can be used to determine the cancer in the body. According to the World Health Organization, cancer is a leading cause of death worldwide; it accounted for nearly 10 million deaths or nearly one in six deaths in 2020. Lung, breast, colon, rectum, and prostate cancers are some of the common cancers. According to a study published in the Journal of Ovarian Research, ovarian cancer is currently the fifth leading cause of death for women with cancer globally. More than 70% of cases of this cancer are diagnosed at an advanced stage. The human epididymis protein 4 biomarker test (HE4 test) is considered to be the most effective and reliable test for the detection of ovarian and endometrial cancers.
Wide prevalence of cancer is a key driver of the global cancer biomarkers market. According to a World Health Organization report, cancer is the major reason for deaths around the globe after heart issues. Cancer cases are surging due to the increase in trend of smoking, rise in pollution levels, and poor dietary habits. Around 235,760 lung cancer cases were reported in the U.S. in 2021. Furthermore, more than 130,000 people lose their lives every year due to lung cancer in the U.S. Lung cancer cases have been rising in other parts of the world as well, with percentage of people smoking reaching around 19% globally. Around one-third of deaths from cancer are linked to tobacco usage, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. Cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries.
Many pharmaceutical companies are actively investing in the research and development of novel biomarkers for cancer diagnosis and treatment. Various potential candidates are nearing the end of their development. This is expected to significantly boost the market. According to the National Library of Medicine, approximately 1,515 cancer biomarkers are in clinical trials. For instance, Lund University Hospital, in collaboration with the South Sweden Breast Cancer Group, is conducting clinical trials to compare the efficacy and tolerability of atorvastatin (in phase 2). Introduction of new biomarkers for cancer screening and diagnosis is expected to propel the oncology biomarkers market growth. Additionally, increase in product launches and diagnostics pertaining to cancer biomarkers is estimated to drive the market. For instance, in April 2021, F. Hoffmann-La Roche Ltd. (Switzerland) launched Elecsys Anti-p53 immunoassay to aid the diagnosis of various types of cancers.
In terms of type, the global cancer biomarkers market has been classified into protein, genetic, and others. The protein segment held major share of the global market in 2021. The segment is expected to maintain its leading position in the global cancer biomarkers market during the forecast period. This can be ascribed to the increase in usage of protein biomarkers in research in cancer treatment. Protein biomarkers are considered the most common biomarkers used for the accurate detection of various types of cancers.
Based on type of cancer, the global cancer biomarkers market has been segmented into lung, breast, leukemia, melanoma, colorectal, prostate, ovarian, liver, and others. The breast cancer segment is projected to dominate the global market during the forecast period. Biomarkers are extensively used to detect breast cancer in patients. Increase in number of patients suffering from breast cancer across the globe is expected to drive the segment during the forecast period. According to the World Health Organization, breast cancer was the most common cancer across the globe in 2021, accounting for 12% of all new annual cancer cases worldwide.
In terms of profiling technology, the global cancer biomarkers market has been classified into omics, imaging, immunoassay, bioinformatics, and others. The omics segment held dominant share of the market in 2021. The segment is expected to grow at a faster pace during the forecast period. Omics technology is highly efficient in the early diagnosis of cancer. Additionally, novel development in profiling technologies for cancer biomarkers is expected to drive the cancer biomarker market size during the forecast period.
North America dominated the global cancer biomarkers market, with more than 30% share in 2021. It is expected to hold major share of the global cancer biomarkers market during the forecast period. High patient population with cancer in the U.S. and Canada and increase in research and development activities in various types of cancer biomarkers are expected to drive the cancer biomarkers market in the region.
Europe is also expected to be a highly attractive region of the global cancer biomarkers market during the forecast period. Increase in prevalence and incidence of cancer in the region is likely to drive the market during the forecast period.
The cancer biomarkers market in Asia Pacific is also anticipated to grow significantly during the forecast period. This can be ascribed to the rise in disposable income, rapid urbanization, increase in health care infrastructure, and distribution and partnership strategies adopted by the players in the region.
The global cancer biomarkers market is consolidated, with the top players accounting for major share. Players are focusing on adopting strategies such as acquisition & collaboration, geographic expansion, growth of distribution channels, and R&D to enhance their share in the global cancer biomarkers market. Key players operating in the global cancer biomarkers market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Merck & Co, Inc., Thermo Fisher Scientific, Inc., Bristol-Myers Squibb Company, PerkinElmer, Inc., Qiagen N.V., Siemens AG, Exact Sciences Corporation, Novartis AG, Bio-Rad Laboratories, Illumina, Agilent Technologies Inc., Hologic, Inc., and bioMérieux SA.
Each of these players has been profiled in the cancer biomarkers market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size Value in 2021 | US$ 12.6 Bn |
| Market Forecast Value in 2031 | More than US$ 31.4 Bn |
| Growth Rate (CAGR) | 9.9% |
| Forecast Period | 2022-2031 |
| Historical Data Available for | 2017-2020 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global market was valued at US$ 12.6 Bn in 2021
The industry is projected to reach more than US$ 31.4 Bn by 2031
The global market grew at a CAGR of 4.5% from 2017 to 2021
The global market is anticipated to grow at a CAGR of 9.9% from 2022 to 2031
Increase in patient population with various type of cancers, rise in geriatric population across the globe, and increase in technological advancements in development of cancer biomarkers
The protein type segment accounted for more than 50% share of the global market in 2021
North America is expected to account for major share of the global cancer biomarkers market during the forecast period
F. Hoffmann-LA Roche Ltd., Thermo Fisher Scientific, Inc., Abbott Laboratories, Merck & Co., Inc Bristol-Myers Squibb Company, PerkinElmer, Inc., Qiagen N.V., Siemens AG, Exact Sciences Corporation, Novartis AG, Bio-Rad Laboratories, Illumina, Agilent Technologies Inc., Hologic, Inc., and bioMérieux SA
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Biomarkers Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Biomarkers Market Analysis and Forecasts, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Cancer Biomarkers Market Analysis and Forecasts, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type, 2017-2031
6.3.1. Protein
6.3.2. Genetic
6.3.3. Others
6.4. Market Attractiveness By Type
7. Global Cancer Biomarkers Market Analysis and Forecasts, By Type of Cancer
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type of Cancer, 2017-2031
7.3.1. Lung
7.3.2. Breast
7.3.3. Leukemia
7.3.4. Melanoma
7.3.5. Colorectal
7.3.6. Prostate
7.3.7. Ovarian
7.3.8. Liver
7.3.9. Others
7.4. Market Attractiveness By Type of Cancer
8. Global Cancer Biomarkers Market Analysis and Forecasts, By Profiling Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Profiling Technology, 2017-2031
8.3.1. Omics
8.3.2. Imaging
8.3.3. Immunoassay
8.3.4. Bioinformatics
8.3.5. Others
8.4. Market Attractiveness By Profiling Technology
9. Global Cancer Biomarkers Market Analysis and Forecasts, By Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Application, 2017-2031
9.3.1. Diagnostics
9.3.2. R&D
9.3.3. Prognostics
9.3.4. Others
9.4. Market Attractiveness By Application
10. Global Cancer Biomarkers Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Cancer Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Type, 2017-2031
11.2.1. Protein
11.2.2. Genetic
11.2.3. Others
11.3. Market Value Forecast By Type of Cancer, 2017-2031
11.3.1. Lung
11.3.2. Breast
11.3.3. Leukemia
11.3.4. Melanoma
11.3.5. Colorectal
11.3.6. Prostate
11.3.7. Ovarian
11.3.8. Liver
11.3.9. Others
11.4. Market Value Forecast By Profiling Technology, 2017-2031
11.4.1. Omics
11.4.2. Imaging
11.4.3. Immunoassay
11.4.4. Bioinformatics
11.4.5. Others
11.5. Market Value Forecast By Application, 2017-2031
11.5.1. Diagnostics
11.5.2. R&D
11.5.3. Prognostics
11.5.4. Others
11.6. Market Value Forecast By Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Type of Cancer
11.7.3. By Profiling Technology
11.7.4. By Application
11.7.5. By Country
12. Europe Cancer Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type, 2017-2031
12.2.1. Protein
12.2.2. Genetic
12.2.3. Others
12.3. Market Value Forecast By Type of Cancer, 2017-2031
12.3.1. Lung
12.3.2. Breast
12.3.3. Leukemia
12.3.4. Melanoma
12.3.5. Colorectal
12.3.6. Prostate
12.3.7. Ovarian
12.3.8. Liver
12.3.9. Others
12.4. Market Value Forecast By Profiling Technology, 2017-2031
12.4.1. Omics
12.4.2. Imaging
12.4.3. Immunoassay
12.4.4. Bioinformatics
12.4.5. Others
12.5. Market Value Forecast By Application, 2017-2031
12.5.1. Diagnostics
12.5.2. R&D
12.5.3. Prognostics
12.5.4. Others
12.6. Market Value Forecast By Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Type of Cancer
12.7.3. By Profiling Technology
12.7.4. By Application
12.7.5. By Country/Sub-region
13. Asia Pacific Cancer Biomarkers Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type, 2017-2031
13.2.1. Protein
13.2.2. Genetic
13.2.3. Others
13.3. Market Value Forecast By Type of Cancer, 2017-2031
13.3.1. Lung
13.3.2. Breast
13.3.3. Leukemia
13.3.4. Melanoma
13.3.5. Colorectal
13.3.6. Prostate
13.3.7. Ovarian
13.3.8. Liver
13.3.9. Others
13.4. Market Value Forecast By Profiling Technology, 2017-2031
13.4.1. Omics
13.4.2. Imaging
13.4.3. Immunoassay
13.4.4. Bioinformatics
13.4.5. Others
13.5. Market Value Forecast By Application, 2017-2031
13.5.1. Diagnostics
13.5.2. R&D
13.5.3. Prognostics
13.5.4. Others
13.6. Market Value Forecast By Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Type of Cancer
13.7.3. By Profiling Technology
13.7.4. By Application
13.7.5. By Country/Sub-region
14. Latin America Cancer Biomarkers Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type, 2017-2031
14.2.1. Protein
14.2.2. Genetic
14.2.3. Others
14.3. Market Value Forecast By Type of Cancer, 2017-2031
14.3.1. Lung
14.3.2. Breast
14.3.3. Leukemia
14.3.4. Melanoma
14.3.5. Colorectal
14.3.6. Prostate
14.3.7. Ovarian
14.3.8. Liver
14.3.9. Others
14.4. Market Value Forecast By Profiling Technology, 2017-2031
14.4.1. Omics
14.4.2. Imaging
14.4.3. Immunoassay
14.4.4. Bioinformatics
14.4.5. Others
14.5. Market Value Forecast By Application, 2017-2031
14.5.1. Diagnostics
14.5.2. R&D
14.5.3. Prognostics
14.5.4. Others
14.6. Market Value Forecast By Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Type of Cancer
14.7.3. By Profiling Technology
14.7.4. By Application
14.7.5. By Country/Sub-region
15. Middle East & Africa Cancer Biomarkers Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Type, 2017-2031
15.2.1. Protein
15.2.2. Genetic
15.2.3. Others
15.3. Market Value Forecast By Type of Cancer, 2017-2031
15.3.1. Lung
15.3.2. Breast
15.3.3. Leukemia
15.3.4. Melanoma
15.3.5. Colorectal
15.3.6. Prostate
15.3.7. Ovarian
15.3.8. Liver
15.3.9. Others
15.4. Market Value Forecast By Profiling Technology, 2017-2031
15.4.1. Omics
15.4.2. Imaging
15.4.3. Immunoassay
15.4.4. Bioinformatics
15.4.5. Others
15.5. Market Value Forecast By Application, 2017-2031
15.5.1. Diagnostics
15.5.2. R&D
15.5.3. Prognostics
15.5.4. Others
15.6. Market Value Forecast By Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type
15.7.2. By Type of Cancer
15.7.3. By Profiling Technology
15.7.4. By Application
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share/Ranking Analysis By Company (2021)
16.3. Company Profiles
16.3.1. F. Hoffmann-LA Roche Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Thermo Fisher Scientific, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Abbott Laboratories
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. Bristol-Myers Squibb Company
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. PerkinElmer, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. Qiagen N.V.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. Siemens AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Exact Sciences Corporation
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
16.3.9. Novartis AG
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Strategic Overview
16.3.10. Bio-Rad Laboratories
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Strategic Overview
16.3.11. Illumina
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. SWOT Analysis
16.3.11.4. Strategic Overview
16.3.12. Agilent Technologies Inc.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. SWOT Analysis
16.3.12.4. Strategic Overview
16.3.13. Hologic, Inc.
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. SWOT Analysis
16.3.13.4. Strategic Overview
16.3.14. bioMérieux SA
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. SWOT Analysis
16.3.14.4. Strategic Overview
List of Tables
Table 01: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 02: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
Table 03: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 04: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 05: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 08: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
Table 09: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 10: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 11: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
Table 12: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 13: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
Table 14: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 15: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 16: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 18: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
Table 19: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 20: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 21: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 23: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
Table 24: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 25: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 26: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 28: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
Table 29: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 30: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
List of Figures
Figure 01: Global Cancer Biomarkers market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Cancer Biomarkers market Value Share, by Type, 2021
Figure 03: Global Cancer Biomarkers market Value Share, by Profiling Technology, 2021
Figure 04: Global Cancer Biomarkers market Value Share, by Cancer, 2021
Figure 05: Global Cancer Biomarkers market Value Share, by Application, 2021
Figure 06: Global Cancer Biomarkers market Value Share, by Region, 2021
Figure 07: Global Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
Figure 08: Global Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
Figure 09: Global Cancer Biomarkers Market Value (US$ Mn), by Protein, 2017-2031
Figure 10: Global Cancer Biomarkers Market Value (US$ Mn), by Genetic, 2017-2031
Figure 11: Global Cancer Biomarkers Market Value (US$ Mn), by Others, 2017-2031
Figure 12: Global Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
Figure 13: Global Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
Figure 14: Global Cancer Biomarkers Market Revenue (US$ Mn), by Lung, 2017-2031
Figure 15: Global Cancer Biomarkers Market Revenue (US$ Mn), by Breast, 2017-2031
Figure 16: Global Cancer Biomarkers Market Revenue (US$ Mn), by Leukemia, 2017-2031
Figure 17: Global Cancer Biomarkers Market Revenue (US$ Mn), by Melonoma, 2017-2031
Figure 18: Global Cancer Biomarkers Market Revenue (US$ Mn), by Colorectal, 2017-2031
Figure 19: Global Cancer Biomarkers Market Revenue (US$ Mn), by Prostate, 2017-2031
Figure 20: Global Cancer Biomarkers Market Revenue (US$ Mn), by Ovarian, 2017-2031
Figure 21: Global Cancer Biomarkers Market Revenue (US$ Mn), by Liver, 2017-2031
Figure 22: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017-2031
Figure 23: Global Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
Figure 24: Global Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
Figure 25: Global Cancer Biomarkers Market Revenue (US$ Mn), by Omics, 2017-2031
Figure 26: Global Cancer Biomarkers Market Revenue (US$ Mn), by Imaging, 2017-2031
Figure 27: Global Cancer Biomarkers Market Revenue (US$ Mn), by Immunoassay, 2017-2031
Figure 28: Global Cancer Biomarkers Market Revenue (US$ Mn), by Bioinformatics, 2017-2031
Figure 29: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017-2031
Figure 30: Global Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
Figure 31: Global Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
Figure 32: Global Cancer Biomarkers Market Revenue (US$ Mn), by Diagnostics, 2017-2031
Figure 33: Global Cancer Biomarkers Market Revenue (US$ Mn), by R&D, 2017-2031
Figure 34: Global Cancer Biomarkers Market Revenue (US$ Mn), by Prognostics, 2017-2031
Figure 35: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017-2031
Figure 36: Global Cancer Biomarkers Market Value Share Analysis, by Region, 2021 and 2031
Figure 37: Global Cancer Biomarkers Market Attractiveness Analysis, by Region, 2022-2031
Figure 38: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
Figure 39: North America Cancer Biomarkers Market Value Share Analysis, by Country, 2021 and 2031
Figure 40: North America Cancer Biomarkers Market Attractiveness Analysis, by Country, 2022-2031
Figure 41: North America Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
Figure 42: North America Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
Figure 43: North America Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
Figure 44: North America Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
Figure 45: North America Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
Figure 46: North America Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
Figure 47: North America Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
Figure 48: North America Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
Figure 49: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
Figure 50: Europe Cancer Biomarkers Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 51: Europe Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 52: Europe Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
Figure53 11: Europe Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
Figure 54: Europe Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
Figure 55: Europe Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
Figure 56: Europe Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
Figure 57: Europe Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
Figure 58: Europe Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
Figure 59: Europe Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
Figure 60: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
Figure 61: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 62: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 63: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
Figure 64: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
Figure 65: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
Figure 66: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
Figure 67: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
Figure 68: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
Figure 69: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
Figure 70: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
Figure 71: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
Figure 72: Latin America Cancer Biomarkers Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
Figure 73: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
Figure 74: Latin America Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
Figure 75: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
Figure 76: Latin America Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
Figure 77: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
Figure 78: Latin America Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
Figure 79: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
Figure 80: Latin America Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
Figure 81: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
Figure 82: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
Figure 83: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
Figure 84: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
Figure 85: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
Figure 86: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
Figure 87: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
Figure 88: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
Figure 89: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
Figure 90: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
Figure 91: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
Figure 92: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cancer Biomarkers Market
